By Cliff Peale
The Cincinnati Enquirer
Procter & Gamble Co.'s skin patch to help increase the sex drive of post-menopausal women is being tested in three countries and still is several years away from the marketplace.
Intrinsa, a testosterone patch worn on the abdomen, could help as many as 15 million female consumers, and provide billions of dollars in sales to P&G, the company said last year when recruiting participants for late-stage Phase III clinical trials.
The trials are taking place in the United States, Australia and Canada, P&G said. After they are complete, it will apply to the U.S. Food and Drug Administration for approval.
Four out of every 10 women aged 18 to 59 experience some sexual dysfunction, such as low libido or inability to achieve orgasm. P&G is developing Intrinsa with Watson Pharmaceuticals, which originally developed the technology.
TODAY'S BUSINESS HEADLINES
Firms hunt for Viagra for women
P&G testing testosterone patch
War fears bite into growth, spending
February U.S. auto sales flag
What's the Buzz?
Morning Memo: Hot tips & news to start your business day
Theater chains hope moviegoers will sit for ads
ImClone founder pleads guilty
Anthem bucks trend, grows as others shrink
Anthem largest Indiana company
Airline performance improves